Beauty Farm Medical and Health Industry Inc. (Beauty Farm Medical) has released its monthly return for March 2026, highlighting a targeted share repurchase that modestly trimmed the company’s outstanding equity while leaving its authorised capital unchanged.

Authorised and issued capital • Authorised share capital remained at 10.00 billion ordinary shares with a par value of USD 0.000005 each, equivalent to USD 50,000. • The number of issued shares (excluding treasury stock) fell by 90,000 to 250.44 million, reflecting a 0.04 % reduction from February’s 250.53 million. • Total issued shares, including treasury stock, stayed at 251.59 million, as the repurchased shares were transferred to treasury. Treasury shares increased to 1.16 million, or roughly 0.46 % of total issued capital.

Repurchase details • 60,000 shares were bought back on 30 March at HK$19.1533 each, and another 30,000 shares on 31 March at HK$20.1707. • Aggregate consideration for the month’s buy-backs reached approximately HK$1.75 million, translating to an average purchase price of HK$19.49 per share.

Regulatory compliance • Beauty Farm Medical confirmed that its public float continues to meet the Hong Kong Main Board’s minimum 25 % requirement as of 31 March 2026. • No movements were recorded in share option schemes, warrants, convertibles, or other equity-linked instruments during the period.

The filing, dated 2 April 2026 and signed by Director Li Yang, affirms that all repurchase activities complied with applicable listing rules and corporate authorisations.